Meet the JAKs

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Cytokine Signaling Plays a Key Role in the Pathogenesis of Rheumatoid Arthritis (RA)

Janus Kinases (JAKs)

JAK Inhibitor Animation

Targeting JAK Inhibitors vs Traditional Biologic Therapies

JAK Inhibitors Approved by EMA

Signaling Pathways of Different JAKs

JAK Inhibitors in Latest Stage of Development in RA

Selective Targeting of Different JAKs

Targeting Different JAKs: Tofacitinib and Baricitinib

Tofacitinib in Previously Treated Patients

Tofacitinib in Patients With No Prior MTX Treatment

Select Phase 3 Trials of Baricitinib in RA

Targeting Different JAKs: Upadacitinib and Filgotinib

Upadacitinib in Patients Treated Previously With bDMARD or csDMARD: Phase 3 Studies

Upadacitinib in Patients With No Prior MTX: Phase 3 Study SELECT-EARLY

Safety of Upadacitinib: SELECT-EARLY

Early Use of JAK inhibitors: Expert Perspective

Filgotinib in Patients With Prior bDMARDs: Phase 3 Study

Targeting Different JAKs: Peficitinib

Phase 3 Trials of Peficitinib in RA

Selective JAK Inhibition and Clinical Efficacy

Safety of JAK Inhibitors

Safety of JAK Inhibitors (cont)

JAK Inhibitors in RA: Addressing Unmet Needs

JAK Inhibitors in RA: Addressing Unmet Needs (cont)

Concluding Remarks

Abbreviations

Abbreviations (cont)